<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PCR was used to screen EBV-positive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> from endemic and <z:hpo ids='HP_0003745'>sporadic</z:hpo> Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients, including EBV-positive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> derived from patients with <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Only 10% of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:hpo ids='HP_0002665'>lymphomas</z:hpo> from either North America (1/15) or South America (2/14) were associated with the type 2 EBV strain, whereas 50% (8/16) of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> from equatorial Africa and 46% (10/22) of HIV-associated <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were positive for the type 2 strain </plain></SENT>
<SENT sid="2" pm="."><plain>These data, in conjunction with previous reports, suggest that the proportions of strain types in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> reflect the proportions of strain types in peripheral lymphocytes, and not simply the prevailing regional strain </plain></SENT>
<SENT sid="3" pm="."><plain>The increased association of the type 2 strain in lymphocytes and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> from HIV-infected individuals and from Africa may be a result of intermittent (<z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e>) or continuous (HIU) compromise of immune function in these populations </plain></SENT>
</text></document>